The KCTD12 Knockout Jurkat Polyclonal Cells, derived from Homo sapiens, are a CRISPR/Cas9-edited polyclonal knockout cell population in which the KCTD12 gene has been disrupted in the Jurkat T lymphoblastoid cell line. This loss-of-function model enables the investigation of KCTD12-dependent cellular processes in a heterogeneous genetic background, avoiding the biases of monoclonal selection.
Jurkat cells, originally established from a patient with acute T cell leukemia, grow as suspension lymphoblasts and are a cornerstone model for studying T cell receptor signaling, apoptosis, and cytokine responses. Their robust proliferation and receptivity to genetic manipulation make them an optimal host for CRISPR/Cas9-mediated gene disruption in immunological and cancer research.
KCTD12 encodes an auxiliary subunit of metabotropic GABA-B receptors, where it interacts with GABBR1 and GABBR2 to enhance agonist potency and shape receptor desensitization kinetics. This interaction modulates downstream effectors including G protein-coupled inward rectifying potassium (GIRK) channels and adenylyl cyclase, resulting in altered cAMP production. In parallel, KCTD12 serves as a substrate adaptor for the Cullin3 ubiquitin ligase complex, recruiting targets such as RhoA for ubiquitination and proteasomal degradation, thereby linking GABA-B signaling to the ubiquitin-proteasome system and RhoA signaling, with potential implications for mTOR pathway cross-regulation. KCTD12 can also hetero-oligomerize with related KCTD proteins like KCTD16, fine-tuning receptor pharmacology.
Within Jurkat T cells, KCTD12 ablation facilitates the study of GABA-B receptor functions in lymphocytes, an area critical for understanding neuroimmune interactions. Given the leukemic origin of these cells, the knockout model is particularly apt for exploring whether KCTD12 contributes to T cell leukemia pathology, potentially via RhoA-dependent migration, cytoskeletal reorganization, or cell survival signals.
These polyclonal knockout cells are well-suited for a range of experimental applications, from pharmacological profiling of GABA-B ligands using cAMP accumulation assays to co-immunoprecipitation and ubiquitination assays that probe Cullin3 substrate selection. Additional uses include flow cytometry-based viability and proliferation screens in drug sensitivity testing for neurological disorders, as well as migration assays to assess RhoA-mediated motility. For further details, please contact Ascent Research.
